American Oncology Network | Messino Cancer Centers

Research site

(Unclaimed)

Location

551 Brevard Road, Asheville, North Carolina, United States of America

Site insights

Top conditions

Top treatments

Atezolizumab

Ibrutinib

Pembrolizumab

Trastuzumab

Crizotinib

Ipatasertib

Paclitaxel

Dabrafenib

Exemestane

Trametinib

Parent organization

This site is a part of American Oncology Network

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 40 total trials

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

To evaluate whether Fuzuloparib plus AA-P is superior to placebo plus AA-P as first-line treatment by assessment of radiographic progression-free sur...

Active, not recruiting

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Drug: Fuzuloparib Placebo， Abiraterone acetate and Prednisone

Drug: Fuzuloparib , Abiraterone acetate and Prednisone

A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC

This study is for patients with advanced/metastatic non-small cells lung cancer (NSCLC) who have not received any treatment through the vein for the...

Enrolling

NSCLC

Drug: Carboplatin

Drug: Pemetrexed

A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer (IMforte)

Study GO43104 is a Phase III, randomized, open-label, multicenter study of lurbinectedin in combination with atezolizumab compared with atezolizumab...

Active, not recruiting

Small-Cell Lung Cancer

Drug: Atezolizumab

Drug: Lurbinectedin

A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy (Astefania)

This is a Phase III, two-arm, randomized, double-blind placebo-controlled study in participants with HER2-positive primary breast cancer who have rec...

Active, not recruiting

Breast Cancer

Drug: Trastuzumab Emtansine

Drug: Placebo

Locations recently updated

A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with end...

Enrolling

Early Breast Cancer

Drug: Endocrine Therapy of Physician's Choice

Drug: Abemaciclib

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% (RELATIVITY1093)

The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy...

Enrolling

Non-small Cell Lung Cancer

Drug: Relatlimab

Drug: Nivolumab

A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) (ASC4START)

The study is designed to compare the tolerability of asciminib versus nilotinib for the treatment of newly diagnosed, previously untreated patients w...

Active, not recruiting

Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

Drug: Nilotinib

Drug: Asciminib

Phase 2 Study of DKN-01 in Colorectal Cancer (DeFianCe)

This is a Phase 2 randomized, open-label, two-part, multicenter study with a safety run-in to evaluate efficacy and safety of DKN-01 plus FOLFIRI/FOL...

Active, not recruiting

Colorectal Adenocarcinoma

Colo-rectal Cancer

Drug: Bevacizumab

Drug: FOLFOX

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

This study will evaluate the efficacy, safety, and pharmacokinetics of DS-1062a versus docetaxel in participants with previously treated advanced or...

Active, not recruiting

Non-small Cell Lung Cancer

Drug: Docetaxel

Drug: DS-1062a

Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma (FIRST-308)

This study is a Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician...

Enrolling

Cholangiocarcinoma

Drug: Physician's Choice

Drug: Tinengotinib 8 mg

Status recently updated

Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (STAR-121)

The primary objective of this study is to compare the effect of zimberelimab (ZIM) and domvanalimab (DOM) in combination with chemotherapy relative t...

Active, not recruiting

Enrolling

Non-small Cell Lung Cancer

Drug: Domvanalimab

Drug: Nab-paclitaxel